



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: AKHVERDIAN ET AL.	
	Art Unit: 1632
Application No.: 10/673,786	Examiner: [to be assigned]
Filing Date: September 30, 2003	Atty. Docket: US-115
Title: METHOD FOR PRODUCING L-THREONINE USING BACTERIA BELONGING TO THE GENUS ESCHERICHIA	

CLAIM FOR PRIORITY UNDER 35 U.S.C. § 119 IN UTILITY APPLICATION

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Priority under 35 U.S.C. § 119 is hereby claimed to the following priority document(s), filed in a foreign country within one (1) year prior to the filing of the above-referenced United States utility patent application (35 U.S.C. § 172):

Country	Priority Document Appl. No.	Filing Date
Russia	2002-104983	February 27, 2002

A certified copy of each listed priority document is submitted herewith. Prompt acknowledgment of this claim and submission is respectfully requested.

Respectfully submitted,



Shelly Guest Cermak
Reg. No. 39,571

Date: January 8, 2004

PTO Customer Number: 000038108
Ajinomoto U.S.A., Inc.
1120 Connecticut Avenue, Ste. 1010
Washington, D.C. 20036
202.457.0284



Наш № 20/12-902

«6» декабря 2002 г.

СПРАВКА

Федеральный институт промышленной собственности (далее – Институт) настоящим удостоверяет, что приложенные материалы являются точным воспроизведением первоначального описания, формулы, реферата и чертежей (если имеются) заявки №2002104983 на выдачу патента на изобретение, поданной в Институт в феврале месяце 27 дня 2002 года (27.02.2002).

Название изобретения:

METHOD FOR PRODUCING L-THREONINE
USING BACTERIA BELONGING TO THE
GENUS ESCHERICHIA

Заявитель:

Закрытое акционерное общество «Научно-
исследовательский институт Аджиномото-
Генетика»

Действительные авторы:

АХВЕРДЯН Валерий Завенович
САВРАСОВА Екатерина Алексеевна
КАПЛАН Алла Марковна
ЛОБАНОВ Андрей Олегович
КОЗЛОВ Юрий Иванович



Заведующий отделом 20

А.Л.Журавлев

METHOD FOR PRODUCING L-THREONINE USING BACTERIA BELONGING TO THE GENUS *ESCHERICHIA*

5 Technical field

The present invention relates to biotechnology, specifically to a method for producing L-amino acids by fermentation and more specifically to a gene derived from bacterium *Escherichia coli*. The gene is useful for improvement of L-amino acid productivity, for example, L-threonine.

10 Background art

Conventionally L-amino acids have been industrially produced by method of fermentation utilizing strains of microorganisms obtained from natural sources or mutants of the same especially modified to enhance L-amino acid productivity.

To enhance L-amino acid productivity has been used, for example, amplification
15 of biosynthetic genes by transformation of microorganism by recombinant DNA (see, for example, US patent No. 4,278,765). These techniques based on the increasing of activities of the enzymes involved in amino acid biosynthesis and/or desensitizing the target enzymes to the feedback inhibition by produced L-amino acid or its by-products (see, for example, Japanese Laid-open application No56-18596 (1981), WO 95/16042 or
20 US patent Nos. 5,661,012 and 6,040,160).

Various strains used for production of L-threonine by fermentation are known. There are strains with increased activities of the enzymes involved in L-threonine biosynthesis (US patents 5,175,107; 5,661,012; 5,705,371; 5,939,307; EP0219027), strains resistant to some chemicals such as L-threonine and its analogs (WO0114525A1,
25 EP301572A2, US 5,376,538), strains with the target enzymes desensitized to the feedback inhibition by produced L-amino acid or its by-products (US patents 5,175,107; 5,661,012), strains with inactivated threonine degradation enzymes (US patents 5,939,307; 6,297,031).

The known threonine producing strain VKPM B-3996 (US patents 5,175,107,
30 and 5,705,371) is the best threonine producer at present. For construction of the strain VKPM B-3996 several mutations and a plasmid described below were introduced in the parent strain *E. coli* K-12 (VKPM B-7). Mutant *thrA* gene (mutation *thrA442*) encodes aspartokinase homoserine dehydrogenase I resistant to feedback inhibition by threonine.

Mutant *ilvA* gene (mutation *ilvA442*) encodes threonine deaminase with low activity leading to low rate of isoleucine biosynthesis and to leaky phenotype of isoleucine starvation. In bacteria with *ilvA442* mutation transcription of *thrABC* operon isn't repressed by isoleucine and therefore is very efficient for threonine production.

5 Inactivation of *tdh* gene leads to prevention of the threonine degradation. The genetic determinant of saccharose assimilation (*scrKYABR* genes) was transferred to said strain. To increase expression of genes controlling threonine biosynthesis, plasmid pVIC40 containing mutant threonine operon *thrA442BC* was introduced in the intermediate strain TDH6. The amount of L-threonine accumulated during fermentation of the strain
10 reaches up to 85 g/l.

The present inventors obtained, with respect to *E. coli* K-12, a mutant having a mutation, *thrR* (herein referred to as *rhtA23*) that is concerned in resistance to high concentrations of threonine or homoserine in a minimal medium (Astaurova, O.B. et al., Appl. Bioch. And Microbiol., 21, 611-616 (1985)). The mutation improved the
15 production of L-threonine (SU Patent No. 974817), homoserine and glutamate (Astaurova, O.B. et al., Appl. Bioch. And Microbiol., 27, 556-561, 1991, EP 1013765 A) by the respective *E. coli* producing strain such as the strain VKPM-3996.

Furthermore, the present inventors have revealed that the *rhtA* gene exists at 18 min on *E. coli* chromosome close to the *glnHPQ* operon that encodes components of the
20 glutamine transport system, and that the *rhtA* gene is identical to ORF1 (*ybiF* gene, numbers 764 to 1651 in the GenBank accession number AAA218541, gi:440181), located between *pexB* and *ompX* genes. The unit expressing a protein encoded by the ORF1 has been designated as *rhtA* (rht: resistance to homoserine and threonine) gene. Also, the present inventors have found that the *rhtA23* mutation is an A-for-G
25 substitution at position -1 with respect to the ATG start codon (ABSTRACTS of 17th International Congress of Biochemistry and Molecular Biology in conjugation with 1997 Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco, California August 24-29, 1997, abstract No. 457, EP 1013765 A).

30 In the conditions when the mainstream threonine biosynthetic pathway is studied and optimized in a great extent, the further improvement of threonine producing strain could be done by supplementing bacterium with increased amount of distant precursors of threonine such as aspartate.

It is known that aspartate is a donor of carbon for synthesis of the amino acids of aspartate family (threonine, methionine, lysine), and diaminopimelate, compound a

constituent of the bacterial cell wall. These syntheses are performed by complex pathway with several branch points and extremely sensitive regulatory scheme. In branch point of aspartate, aspartate semialdehyde, homoserine, there are as many isozymes as there are amino acids deriving from this biosynthetic step. The aspartokinase homoserine dehydrogenase I encoded by (part of *thrABC* operon) performs first and third reactions of threonine biosynthesis. Threonine and isoleucine regulate the expression of aspartokinase homoserine dehydrogenase I, and threonine inhibits both activities to catalyze the above-mentioned reactions (*Escherichia coli* and *Salmonella*, Second Edition, Editor in Chief: F.C.Neidhardt, ASM Press, Washington D.C., 1996).

Two genes are involved in the formation of aspartate – aspartate aminotransferase (aspartate transaminase) encoded by *aspC* gene and aspartase, which is a product of *aspA* gene. Aspartate aminotransferase converts oxaloacetate to aspartate. Aspartase converts fumarate to aspartate.

Effect of amplification of *aspC* gene on production of L-lysine – an amino acid of aspartate family – is disclosed. Amplification of *aspC* gene was used for L-lysine production by *E.coli* (US patent 6,040,160). Coryneform bacteria harboring an aspartokinase and enhanced DNA sequence coding for several enzymes including aspartate aminotransferase was used for L-lysine production (US patent 6,004,773).

It was noticed that aspartate aminotransferase could be useful for production of L-threonine and L-lysine by coryneform bacteria (US patent 4,980,285).

But up to date there is no report of using the bacterium belonging to the genus *Escherichia* with enhanced aspartate aminotransferase activity for production of L-threonine.

Disclosure of the invention

An object of present invention is to enhance the productivity of L- threonine producing strains and to provide a method for producing L-threonine using these strains.

This aim was achieved by finding that the *aspC* gene encoding aspartate aminotransferase cloned on a low copy vector can enhance L-threonine production.

Thus the present invention has been completed.

The present inventions are as follows:

1). An L-threonine producing bacterium belonging to the genus *Escherichia*, wherein the bacterium has been modified to enhance an activity of aspartate aminotransferase.

2). The bacterium according to 1), the activity of aspartate aminotransferase is enhanced by increasing expression amount of an aspartate aminotransferase gene.

3). The bacterium according to 1), wherein the activity of aspartate aminotransferase is increased by increasing copy number of the aspartate aminotransferase gene or modifying an expression control sequence of the gene so that the expression of the gene should be enhanced.

4). The bacterium according to 3), wherein the copy number is increased by transformation of the bacterium with a low copy vector containing the gene.

5). The bacterium according to 2) to 4), the aspartate aminotransferase gene is originated from a bacterium belonging to the genus *Escherichia*.

6). The bacterium according to 5), wherein the aspartate aminotransferase gene encodes the following protein (A) or (B):

(A) a protein, which comprises the amino acid sequence shown in SEQ ID NO: 2 in Sequence listing;

(B) a protein which comprises an amino acid sequence including deletion, substitution, insertion or addition of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 2 in Sequence listing, and which has an activity of aspartate aminotransferase.

7). The bacterium according to 5), wherein the aspartate aminotransferase gene comprises the following DNA (a) or (b):

(a) a DNA which comprises a nucleotide sequence of the nucleotides 1 to 1196 in SEQ ID NO: 1; or

(b) a DNA which is hybridizable with a nucleotide sequence of the nucleotides 1-1196 in SEQ ID NO:1 or a probe which can be prepared from the nucleotide sequence under the stringent conditions and codes for a protein having an activity of aspartate aminotransferase.

8). The bacterium according to 7), wherein the stringent conditions is a condition in which washing is performed at 60°C, and at a salt concentration corresponding to 1 x SSC and 0.1 % SDS.

9). The bacterium according to 1) to 8), wherein the bacterium has been further modified to enhance expression of one or more genes selected from the group consisting of

- the mutant *thrA* gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine;
- the *thrB* gene which codes for homoserine kinase;
- the *thrC* gene which codes for threonine synthase;
- the *rhtA* gene, which codes for putative transmembrane protein.

10). The bacterium according to 9), wherein the bacterium has been modified to increase expression amount of the mutant *thrA* gene, the *thrB* gene, the *thrC* gene and the *rhtA* gene.

11). A method for producing L- threonine, which comprises cultivating the bacterium according to 1) to 10) in a culture medium to produce and accumulate L-threonine in the culture medium, and collecting the L-threonine from the culture medium.

The present invention will be explained in detail below.

The bacterium of the present invention is an L-threonine producing bacterium belonging to the genus *Escherichia*, wherein the bacterium has been modified to enhance an activity of aspartate aminotransferase.

20 The bacterium belonging to the genus *Escherichia* that can be used in the present invention is not particularly limited, however for example, bacteria described by Neidhardt, F.C. et al. (*Escherichia coli* and *Salmonella typhimurium*, American Society for Microbiology, Washington D.C., 1208, Table 1) can be mentioned.

25 In the present invention, "L-threonine producing bacterium" means a bacterium, which has an ability to accumulate L-threonine in a medium, when the bacterium of the present invention is cultured in the medium. The L-threonine producing ability may be imparted or enhanced by breeding.

30 Term "activity of aspartate aminotransferase" means activity to catalyze the reaction of formation the aspartate from oxaloacetate and L-glutamate with release of α -ketoglutarate using pyridoxal 5'-phosphate.

The term "modified to enhance an activity of aspartate aminotransferase" means that the activity per cell has become higher than that of a non-modified strain, for example, a wild-type strain. For example, there can be mentioned a case where number of aspartate aminotransferase molecules per cell increases, a case where specific activity

per aspartate aminotransferase molecule increases and so forth. Further, as a wild-type strain that serves as an object for comparison, for example, the *Escherichia coli* K-12 can be mentioned. As a result of enhancement of intracellular activity of aspartate aminotransferase, there are obtained an effect that the amount of L-threonine accumulation in a medium increases.

Enhancement of aspartate aminotransferase activity in a bacterial cell can be attained by enhancement of expression amount of a gene coding for aspartate aminotransferase. As the aspartate aminotransferase gene, any of genes derived from bacteria belonging to the genus *Escherichia* and genes derived from other bacteria such as coryneform bacteria can be used. Among these, genes derived from bacteria belonging to the genus *Escherichia* are preferred.

As the gene coding for aspartate aminotransferase of *Escherichia coli*, *aspC* has already been elucidated (nucleotide numbers 983742 to 984932 in the sequence of GenBank accession NC_000913.1, gi:16128895). Therefore, *aspC* gene can be obtained by PCR (polymerase chain reaction; refer to White, T.J. *et al.*, *Trends Genet.*, 5, 185 (1989)) utilizing primers prepared based on the nucleotide sequence of the gene. Genes coding for aspartate aminotransferase of other microorganisms can be obtained in a similar manner.

The *aspC* gene originated from *Escherichia coli* is exemplified by a DNA which encodes the following protein (A) or (B):

(A) a protein, which comprises the amino acid sequence shown in SEQ ID NO: 2 in Sequence listing;

(B) a protein which comprises an amino acid sequence including deletion, substitution, insertion or addition of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 2 in Sequence listing, and which has an activity of aspartate aminotransferase.

The number of "several" amino acids differs depending on the position or the type of amino acid residues in the three dimensional structure of the protein. It may be 2 to 30, preferably 2 to 15, and more preferably 2 to 5 for the protein (A). This is because of the following reason. Some amino acids have high homology to one another and the difference in such an amino acid does not greatly affect the three dimensional structure of the protein and its activity. Therefore, the protein (B) may be one which has homology of not less than 30 to 50 %, preferably 50 to 70 % with respect to the entire

amino acid residues for constituting aspartate aminotransferase, and which has the activity of aspartate aminotransferase.

The DNA, which codes for the substantially same protein as the aspartate aminotransferase described above, may be obtained, for example, by modifying the nucleotide sequence of DNA coding for aspartate aminotransferase (SEQ ID NO: 1), for example, by means of the site-directed mutagenesis method so that one or more amino acid residues at a specified site involve deletion, substitution, insertion, or addition. DNA modified as described above may be obtained by the conventionally known mutation treatment. Such treatment includes treatment the DNA coding for proteins of present invention with hydroxylamin or treatment the bacterium harboring the DNA with UV irradiation or reagent such as N-methyl-N'-nitro-N-nitrosoguanidine or nitrous acid.

A DNA coding for substantially the same protein as aspartate aminotransferase can be obtained by expressing a DNA having such a mutation as described above in an appropriate cell, and investigating activity of an expressed product. A DNA coding for substantially the same protein as aspartate aminotransferase can also be obtained by isolating a DNA that is hybridizable with a probe having a nucleotide sequence comprising, for example, the nucleotide sequence shown in Sequence Listing as SEQ ID NO: 1, under the stringent conditions, and codes for a protein having the aspartate aminotransferase activity, from DNA coding for aspartate aminotransferase having a mutation or from a cell harboring it. The "stringent conditions" referred to herein is a condition under which so-called specific hybrid is formed, and non-specific hybrid is not formed. It is difficult to clearly express this condition by using any numerical value. However, for example, the stringent conditions are exemplified by a condition under which DNAs having high homology, for example, DNAs having homology of not less than 50% are hybridized with each other, but DNAs having homology lower than the above are not hybridized with each other. Alternatively, the stringent conditions are exemplified by a condition under which DNAs are hybridized with each other at a salt concentration corresponding to an ordinary condition of washing in Southern hybridization, i.e., 1 x SSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS, at 60°C.

As a probe, a partial sequence of the nucleotide sequence of SEQ ID NO: 1 can also be used. Such a probe may be prepared by PCR using oligonucleotides produced based on the nucleotide sequence of SEQ ID NO: 1 as primers, and a DNA fragment containing the nucleotide sequence of SEQ ID NO: 1 as a template. When a DNA

fragment in a length of about 300 bp is used as the probe, the conditions of washing for the hybridization consist of, for example, 50°C, 2 x SSC and 0.1% SDS.

The substitution, deletion, insertion, or addition of nucleotide as described above also includes mutation, which naturally occurs (mutant or variant), for example, on the basis of the individual difference or the difference in species or genus of bacterium, which harbors aspartate aminotransferase.

Transformation of a bacterium with DNA coding for protein means introduction of the DNA into bacterium cell for example by conventional methods to increase expression of the gene coding for the protein of present invention and to enhance the activity of the protein in the bacterial cell.

The methods of the enhancement of gene expression include an increasing of the gene copy number. Introduction of a gene into a vector that is able to function in a bacterium belonging to the genus *Escherichia* increases copy number of the gene. For such purposes low copy vectors can be preferably used. The low-copy vector is exemplified by pSC101, pMW118, pMW119 and the like. As the method of transformation, any known methods that have hitherto been reported can be employed. For instance, employable are a method of treating recipient cells with calcium chloride so as to increase the permeability of DNA, which has been reported for *Escherichia coli* K-12 (Mandel, M. and Higa, A., *J. Mol. Biol.*, 53, 159 (1970)).

Besides, enhancement of gene expression can be achieved by introduction of multiple copies of the gene into bacterial chromosome by, for example, method of homologous recombination or the like.

On the other hand, the enhancement of gene expression can be achieved by locating the DNA of the present invention under control of a potent promoter. For example, *lac* promoter, *trp* promoter, *trc* promoter, P_R, P_L promoters of lambda phage are known as potent promoters. Using the potent promoter can be combined with multiplication of gene copies.

Alternatively, a promoter can be enhanced by, for example, introducing a mutation into the promoter to increase a transcription level of a gene located downstream of the promoter. Further, it is known that substitution of several nucleotides in spacer between ribosome binding site (RBS) and start codon and especially the sequences immediately upstream of the start codon profoundly affect the mRNA translatability. For example, a 20-fold range in the expression levels was found, depending on the nature of the three nucleotides preceding the start codon (Gold *et al.*,

Annu. Rev. Microbiol., 35, 365-403, 1981; Hui *et al.*, EMBO J., 3, 623-629, 1984).

Earlier the authors of present invention showed, the *rhtA23* mutation is an A-for-G substitution at position -1 with respect to the ATG start codon (ABSTRACTS of 17th International Congress of Biochemistry and Molecular Biology in conjugation with 1997 Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco, California August 24-29, 1997, abstract No. 457). Therefore, it may be suggested that *rhtA23* mutation enhances the *rhtA* gene expression and, as a consequence, increases the level of resistance to threonine, homoserine and some other substances transported out of cells.

Moreover, it is also possible to introduce nucleotide substitution into a promoter region of the aspartate aminotransferase gene on the bacterial chromosome so that it should be modified into a stronger one. The alteration of expression control sequence can be performed, for example, in the same manner as the gene substitution using a temperature sensitive plasmid, as disclosed in International Patent Publication WO00/18935 and Japanese Patent Publication No. 1-215280.

Increase of copy number of aspartate aminotransferase gene can also be achieved by introducing multiple copies of the aspartate aminotransferase gene into chromosomal DNA of bacterium. In order to introduce multiple copies of the aspartate aminotransferase gene into bacterial chromosome, homologous recombination is carried out by using a sequence whose multiple copies exist in the chromosomal DNA as targets. As sequences whose multiple copies exist in the chromosomal DNA, repetitive DNA, inverted repeats existing at the end of a transposable element can be used. Also, as disclosed in Japanese Patent Laid-open No. 2-109985, it is possible to incorporate the aspartate aminotransferase gene into transposon, and allow it to be transferred to introduce multiple copies of the gene into the chromosomal DNA.

Methods for preparation of plasmid DNA, digestion and ligation of DNA, transformation, selection of an oligonucleotide as a primer and the like may be ordinary methods well known to one skilled in the art. These methods are described, for instance, in Sambrook, J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989).

The bacterium of the present invention can be obtained by introduction of the aforementioned DNAs into bacterium inherently having ability to produce L- threonine. Alternatively, the bacterium of present invention can be obtained by imparting ability to produce L- threonine to the bacterium already harboring the DNAs.

As a parent strain which is to be enhanced in activity of the aspartate aminotransferase encoded by *aspC* gene, the threonine producing bacteria belonging to the genus *Escherichia* such as *E. coli* strain VKPM B-3996 (US Patent 5, 175, 107, US patent 5,705,371), *E. coli* strain NRRL-21593 (US Patent 5,939,307), *E. coli* strain FERM BP-3756 (US patent 5,474,918), *E. coli* strains FERM BP-3519 and FERM BP-3520 (US patent 5,376,538), *E. coli* strain MG442 (Gusyatiner et al., Genetika (in Russian), 14, 947-956 (1978)), *E. coli* strains VL643 and VL2055 (EP 1149911 A) and the like may be used.

The strain B-3996 is deficient in *thrC* gene and is sucrose-assimilative, in which *ilvA* gene has a leaky mutation. The strain has a mutation in *rhtA* gene, which participates resistance to high concentration of threonine or homoserine. The strain B-3996 harbors the plasmid pVIC40 which had been obtained by inserting *thrA*BC* operon including mutant *thrA* gene encoding aspartokinase homoserine dehydrogenase I which is substantially desensitized feedback inhibition by threonine into RSF1010-derived vector. The strain B-3996 was deposited on November 19, 1987 in All-Union Scientific Center of Antibiotics (Nagatinskaya Street 3-A, 113105 Moscow, Russian Federation) under the accession number RIA 1867. The strain was also deposited in Russian National Collection of Industrial Microorganisms (VKPM) (Dorozhny proezd. 1, Moscow 113545, Russian Federation) under the accession number B-3996.

The bacterium of the present invention is preferably further modified to enhance expression of one or more of the following genes as well as *aspC* gene:

- the mutant *thrA* gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine;
- the *thrB* gene which codes for homoserine kinase;
- the *thrC* gene which codes for threonine synthase;

Another preferred embodiment of the bacterium is modified to enhance the *rhtA* gene, which codes for putative transmembrane protein in addition to enhancement of *aspC* gene. The most preferred embodiment of the bacterium is modified to increase expression amount of the *aspC* gene, the mutant *thrA* gene, the *thrB* gene, the *thrC* gene and the *rhtA* gene.

The method for producing L-threonine of the present invention comprises the steps of cultivating the bacterium of the present invention in a culture medium, to allow L-threonine to be produced and accumulated in the culture medium, and collecting L-threonine from the culture medium.

In the present invention, the cultivation, the collection and purification of L-amino acid from the medium and the like may be performed in a manner similar to the conventional fermentation method wherein an amino acid is produced using a microorganism.

5 A medium used for culture may be either a synthetic medium or a natural medium, so long as the medium includes a carbon source and a nitrogen source and minerals and, if necessary, appropriate amounts of nutrients which the microorganism requires for growth. The carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the mode of assimilation
10 of the used microorganism, alcohol including ethanol and glycerol may be used. As the nitrogen source, various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, and digested fermentative microorganism are used. As minerals, potassium monophosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese
15 sulfate, calcium chloride, and the like are used. As vitamins, thiamine, yeast extract and the like are used.

The cultivation is performed preferably under aerobic conditions such as a shaking culture, and stirring culture with aeration, at a temperature of 20 to 40 °C, preferably 30 to 38 °C. The pH of the culture is usually between 5 and 9, preferably
20 between 6.5 and 7.2. The pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 5-day cultivation leads to the accumulation of the target L-amino acid in the liquid medium.

After cultivation, solids such as cells can be removed from the liquid medium by centrifugation or membrane filtration, and then L- threonine can be collected and
25 purified by ion-exchange, concentration and crystallization methods.

Best Mode for Carrying out the Invention

The present invention will be more concretely explained below with reference to Examples.

Example 1: Cloning of *aspC* gene from *E. coli* into pMW119 vector.

30 The *aspC* gene was obtained from chromosomal DNA of the *E. coli* strain K-12 by PCR using primers shown in SEQ ID NOs: 3 and 4 in the Sequence listing. Obtained DNA fragment was treated with *PvuII* and *EcoRI* restrictases and ligated to the stable

low copy plasmid pMW119 (replicon pSC101) previously treated with *HincII* and *EcoRI* restrictases under control of P_{lac} promoter. Thus, the pMW- P_{lac} -aspC plasmid was obtained.

Also, *aspC* gene was placed under control of the strong P_R promoter of the phage lambda instead of P_{lac} promoter. A DNA duplex containing P_R promoter was formed using chemically synthesized 5'-phosphorylated oligonucleotides shown in the SEQ ID Nos: 5 and 6 in the Sequence listing. Then, the DNA duplex was ligated to the pMW- P_{lac} -aspC plasmid previously treated with *PvuII* and *HindIII* restrictases. Thus the plasmid pM- P_R -aspC was constructed.

Non-regulated high level of *aspC* gene expression could be achieved using these plasmids. The plasmids pMW- P_{lac} -aspC and pM- P_R -aspC are compatible with plasmid pVIC40 (replicon pRSF1010), therefore two plasmids pVIC40 and pMW- P_{lac} -aspC or pVIC40 and pM- P_R -aspC could be maintained in the bacteria simultaneously.

Each of the pMW- P_{lac} -aspC and pM- P_R -aspC plasmid was introduced into streptomycin-resistant threonine producer *E. coli* strain B-3996 (US patent 5,175,107). Thus the strains B-3996(pMW- P_{lac} -aspC) and B-3996(pM- P_R -aspC) were obtained.

Example 2. Effect of the *aspC* gene amplification on threonine production.

The *E. coli* strain VKPM-3996(pM- P_R -aspC) was grown during 18-24 hours at 37 °C on L-agar plates containing streptomycin (100 µg/ml). Then one loop of the cells was transferred to 50 ml of L-broth of the following composition: trypton – 10g/l, yeast extract – 5 g/l, NaCl – 5 g/l. The cells (50 ml, OD₅₄₀ - 2 o.u.) grown at 37 °C within 5 hours on shaker (240 rpm) was used for seeding 450 ml of the medium for fermentation. The batch fermentation was performed in laboratory fermenters having a capacity of 1.0 l under aeration (1/1 vvm) with stirring at a speed of 1200 rpm at 37 °C. The pH value was maintained automatically at 6.6 using 8% ammonia liquor. The results are presented in Table 1.

The composition of the fermentation medium (g/l):

Sucrose	100.0
NH ₄ Cl	1.75
KH ₂ PO ₄	1.0
MgSO ₄ x 7H ₂ O	0.8
FeSO ₄ x 7H ₂ O	0.01

MnSO ₄ x 5H ₂ O	0.01
Mameno(TN)	0.15
Betaine	1.0
L-isoleucine	0.2

- 5 Sucrose and magnesium sulfate are sterilized separately. pH is adjusted to 6.6.

Table 1.

Strain	Additional <i>aspC</i> gene	Time, hours	OD ₅₄₀	Threonine, g/l
B-3996	-	19.1	34.6	45.0
		18.4	33.8	43.8
B-3996 (pMW-P _{lac} - aspC)	+	17.5	29.8	45.2
		18.5	30.6	45.8
		18.5	30.8	45.9
		18.3	30.0	46.2
		18.2±0.5	30.3±0.5	45.9±0.4
B-3996 (pM-P _R - aspC)	+	16.0	32.0	45.4
		18.0	30.8	46.5
		17.8	29.4	45.8
		18.3	30.0	45.2
		17.9±1.0	30.4±1.1	45.6±0.6

SEQUENCE LISTING

<110> Ajinomoto-Genetika Research Institute

5 <120> METHOD FOR PRODUCING L-AMINO ACID USING BACTERIA
BELONGING TO THE GENUS ESCHERICHIA

<130>

10 <140>

<141>

<160> 6

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 1191

<212> DNA

20 <213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1191)

25

<400> 1

	atg ttt gag aac att acc gcc gct cct gcc gac ccg att ctg ggc ctg	48
	Met Phe Glu Asn Ile Thr Ala Ala Pro Ala Asp Pro Ile Leu Gly Leu	
	1 5 10 15	
30	gcc gat ctg ttt cgt gcc gat gaa cgt ccc ggc aaa att aac ctc ggg	96
	Ala Asp Leu Phe Arg Ala Asp Glu Arg Pro Gly Lys Ile Asn Leu Gly	
	20 25 30	
	att ggt gtc tat aaa gat gag acg ggc aaa acc ccg gta ctg acc agc	144
	Ile Gly Val Tyr Lys Asp Glu Thr Gly Lys Thr Pro Val Leu Thr Ser	
35	35 40 45	
	gtg aaa aag gct gaa cag tat ctg ctc gaa aat gaa acc acc aaa aat	192
	Val Lys Lys Ala Glu Gln Tyr Leu Leu Glu Asn Glu Thr Thr Lys Asn	
	50 55 60	
40	tac ctc ggc att gac ggc atc cct gaa ttt ggt cgc tgc act cag gaa	240
	Tyr Leu Gly Ile Asp Gly Ile Pro Glu Phe Gly Arg Cys Thr Gln Glu	
	65 70 75 80	
	ctg ctg ttt ggt aaa ggt agc gcc ctg atc aat gac aaa cgt gct cgc	288
	Leu Leu Phe Gly Lys Gly Ser Ala Leu Ile Asn Asp Lys Arg Ala Arg	
	85 90 95	
45	acg gca cag act ccg ggg ggc act ggc gca cta cgc gtg gct gcc gat	336
	Thr Ala Gln Thr Pro Gly Gly Thr Gly Ala Leu Arg Val Ala Ala Asp	
	100 105 110	
	ttc ctg gca aaa aat acc agc gtt aag cgt gtg tgg gtg agc aac cca	384
	Phe Leu Ala Lys Asn Thr Ser Val Lys Arg Val Trp Val Ser Asn Pro	
50	115 120 125	
	agc tgg ccg aac cat aag agc gtc ttt aac tct gca ggt ctg gaa gtt	432
	Ser Trp Pro Asn His Lys Ser Val Phe Asn Ser Ala Gly Leu Glu Val	
	130 135 140	
	cgt gaa tac gct tat tat gat gcg gaa aat cac act ctt gac ttc gat	480
55	Arg Glu Tyr Ala Tyr Tyr Asp Ala Glu Asn His Thr Leu Asp Phe Asp	
	145 150 155 160	
	gca ctg att aac agc ctg aat gaa gct cag gct ggc gac gta gtg ctg	528
	Ala Leu Ile Asn Ser Leu Asn Glu Ala Gln Ala Gly Asp Val Val Leu	
	165 170 175	
60	ttc cat ggc tgc tgc cat aac cca acc ggt atc gac cct acg ctg gaa	576
	Phe His Gly Cys Cys His Asn Pro Thr Gly Ile Asp Pro Thr Leu Glu	

				180				185				190						
		caa	tgg	caa	aca	ctg	gca	caa	ctc	tcc	ggt	gag	aaa	ggc	tgg	tta	ccg	624
		Gln	Trp	Gln	Thr	Leu	Ala	Gln	Leu	Ser	Val	Glu	Lys	Gly	Trp	Leu	Pro	
				195				200						205				
5		ctg	ttt	gac	ttc	gct	tac	cag	ggg	ttt	gcc	cgt	ggg	ctg	gaa	gaa	gat	672
		Leu	Phe	Asp	Phe	Ala	Tyr	Gln	Gly	Phe	Ala	Arg	Gly	Leu	Glu	Glu	Asp	
			210					215					220					
		gct	gaa	gga	ctg	cgc	gct	ttc	gcg	gct	atg	cat	aaa	gag	ctg	att	gtt	720
		Ala	Glu	Gly	Leu	Arg	Ala	Phe	Ala	Ala	Met	His	Lys	Glu	Leu	Ile	Val	
10			225					230					235				240	
		gcc	agt	tcc	tac	tct	aaa	aac	ttt	ggc	ctg	tac	aac	gag	cgt	gtt	ggc	768
		Ala	Ser	Ser	Tyr	Ser	Lys	Asn	Phe	Gly	Leu	Tyr	Asn	Glu	Arg	Val	Gly	
					245					250					255			
15		gct	tgt	act	ctg	gtt	gct	gcc	gac	agt	gaa	acc	gtt	gat	cgc	gca	ttc	816
		Ala	Cys	Thr	Leu	Val	Ala	Ala	Asp	Ser	Glu	Thr	Val	Asp	Arg	Ala	Phe	
					260					265					270			
		agc	caa	atg	aaa	gcg	gcg	att	cgc	gct	aac	tac	tct	aac	cca	cca	gca	864
		Ser	Gln	Met	Lys	Ala	Ala	Ile	Arg	Ala	Asn	Tyr	Ser	Asn	Pro	Pro	Ala	
				275					280					285				
20		cac	ggc	gct	tct	gtt	gtt	gcc	acc	atc	ctg	agc	aac	gat	gcg	tta	cgt	912
		His	Gly	Ala	Ser	Val	Val	Ala	Thr	Ile	Leu	Ser	Asn	Asp	Ala	Leu	Arg	
			290					295					300					
		gcg	att	tgg	gaa	caa	gag	ctg	act	gat	atg	cgc	cag	cgt	att	cag	cgt	960
		Ala	Ile	Trp	Glu	Gln	Leu	Thr	Asp	Met	Arg	Gln	Arg	Ile	Gln	Arg		
25			305					310				315				320		
		atg	cgt	cag	ttg	ttc	gtc	aat	acg	ctg	cag	gaa	aaa	ggc	gca	aac	cgc	1008
		Met	Arg	Gln	Leu	Phe	Val	Asn	Thr	Leu	Gln	Glu	Lys	Gly	Ala	Asn	Arg	
					325					330					335			
30		gac	ttc	agc	ttt	atc	atc	aaa	cag	aac	ggc	atg	ttc	tcc	ttc	agt	ggc	1056
		Asp	Phe	Ser	Phe	Ile	Ile	Lys	Gln	Asn	Gly	Met	Phe	Ser	Phe	Ser	Gly	
					340				345						350			
		ctg	aca	aaa	gaa	caa	gtg	ctg	cgt	ctg	cgc	gaa	gag	ttt	ggc	gta	tat	1104
		Leu	Thr	Lys	Glu	Gln	Val	Leu	Arg	Leu	Arg	Glu	Glu	Phe	Gly	Val	Tyr	
				355				360						365				
35		gcg	gtt	gct	tct	ggg	cgc	gta	aat	gtg	gcc	ggg	atg	aca	cca	gat	aac	1152
		Ala	Val	Ala	Ser	Gly	Arg	Val	Asn	Val	Ala	Gly	Met	Thr	Pro	Asp	Asn	
			370				375						380					
		atg	gct	ccg	ctg	tgc	gaa	gcg	att	gtg	gca	gtg	ctg	taa				1191
		Met	Ala	Pro	Leu	Cys	Glu	Ala	Ile	Val	Ala	Val	Leu					
40			385				390					395						
		<210>	2															
		<211>	396															
		<212>	PRT															
45		<213>	Escherichia coli															
		<400>	2															
		Met	Phe	Glu	Asn	Ile	Thr	Ala	Ala	Pro	Ala	Asp	Pro	Ile	Leu	Gly	Leu	
		1				5					10				15			
50		Ala	Asp	Leu	Phe	Arg	Ala	Asp	Glu	Arg	Pro	Gly	Lys	Ile	Asn	Leu	Gly	
					20					25					30			
		Ile	Gly	Val	Tyr	Lys	Asp	Glu	Thr	Gly	Lys	Thr	Pro	Val	Leu	Thr	Ser	
				35					40					45				
		Val	Lys	Lys	Ala	Glu	Gln	Tyr	Leu	Leu	Glu	Asn	Glu	Thr	Thr	Lys	Asn	
55			50				55					60						
		Tyr	Leu	Gly	Ile	Asp	Gly	Ile	Pro	Glu	Phe	Gly	Arg	Cys	Thr	Gln	Glu	
			65				70					75				80		
		Leu	Leu	Phe	Gly	Lys	Gly	Ser	Ala	Leu	Ile	Asn	Asp	Lys	Arg	Ala	Arg	
					85						90					95		
60		Thr	Ala	Gln	Thr	Pro	Gly	Gly	Thr	Gly	Ala	Leu	Arg	Val	Ala	Ala	Asp	
					100					105					110			

Phe Leu Ala Lys Asn Thr Ser Val Lys Arg Val Trp Val Ser Asn Pro
 115 120 125
 Ser Trp Pro Asn His Lys Ser Val Phe Asn Ser Ala Gly Leu Glu Val
 130 135 140
 5 Arg Glu Tyr Ala Tyr Tyr Asp Ala Glu Asn His Thr Leu Asp Phe Asp
 145 150 155 160
 Ala Leu Ile Asn Ser Leu Asn Glu Ala Gln Ala Gly Asp Val Val Leu
 165 170 175
 10 Phe His Gly Cys Cys His Asn Pro Thr Gly Ile Asp Pro Thr Leu Glu
 180 185 190
 Gln Trp Gln Thr Leu Ala Gln Leu Ser Val Glu Lys Gly Trp Leu Pro
 195 200 205
 Leu Phe Asp Phe Ala Tyr Gln Gly Phe Ala Arg Gly Leu Glu Glu Asp
 210 215 220
 15 Ala Glu Gly Leu Arg Ala Phe Ala Ala Met His Lys Glu Leu Ile Val
 225 230 235 240
 Ala Ser Ser Tyr Ser Lys Asn Phe Gly Leu Tyr Asn Glu Arg Val Gly
 245 250 255
 20 Ala Cys Thr Leu Val Ala Ala Asp Ser Glu Thr Val Asp Arg Ala Phe
 260 265 270
 Ser Gln Met Lys Ala Ala Ile Arg Ala Asn Tyr Ser Asn Pro Pro Ala
 275 280 285
 His Gly Ala Ser Val Val Ala Thr Ile Leu Ser Asn Asp Ala Leu Arg
 290 295 300
 25 Ala Ile Trp Glu Gln Glu Leu Thr Asp Met Arg Gln Arg Ile Gln Arg
 305 310 315 320
 Met Arg Gln Leu Phe Val Asn Thr Leu Gln Glu Lys Gly Ala Asn Arg
 325 330 335
 30 Asp Phe Ser Phe Ile Ile Lys Gln Asn Gly Met Phe Ser Phe Ser Gly
 340 345 350
 Leu Thr Lys Glu Gln Val Leu Arg Leu Arg Glu Glu Phe Gly Val Tyr
 355 360 365
 Ala Val Ala Ser Gly Arg Val Asn Val Ala Gly Met Thr Pro Asp Asn
 370 375 380
 35 Met Ala Pro Leu Cys Glu Ala Ile Val Ala Val Leu
 385 390 395

<210> 3
 <211> 36
 40 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

45 <400> 3
 gctacttacg aattccgttt gtcatacagtc tcagcc

36

50 <210> 4
 <211> 36
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence:primer

<400> 4
 cctagatcac agctgatgtt tgagaacatt accgcc

36

60 <210> 5
 <211> 36

<212> DNA
<213> Artificial Sequence

<400> 5

5 ttgactatatt tacctctggc ggtgataatg gtccca

36

<210> 6

<211> 40

<212> DNA

10 <213> Artificial Sequence

<400> 6

agcttgggac cattatcacc gccagaggta aaatagtcaa

40

15

What is claimed is:

1). An L-threonine producing bacterium belonging to the genus *Escherichia*,
5 wherein the bacterium has been modified to enhance an activity of aspartate
aminotransferase.

2). The bacterium according to claim 1, the activity of aspartate aminotransferase
is enhanced by increasing expression amount of an aspartate aminotransferase gene.

3). The bacterium according to claims 1, wherein the activity of aspartate
10 aminotransferase is increased by increasing copy number of the aspartate
aminotransferase gene or modifying an expression control sequence of the gene so that
the expression of the gene should be enhanced.

4). The bacterium according to claim 3, wherein the copy number is increased
by transformation of the bacterium with a low copy vector containing the gene.

5). The bacterium according to any of claims 2 to 4, the aspartate
15 aminotransferase gene is originated from a bacterium belonging to the genus
Escherichia.

6). The bacterium according to claim 5, wherein the aspartate aminotransferase
gene encodes the following protein (A) or (B):

20 (A) a protein, which comprises the amino acid sequence shown in SEQ ID NO: 2
in Sequence listing;

(B) a protein, which comprises an amino acid sequence including deletion,
substitution, insertion or addition of one or several amino acids in the amino acid
sequence shown in SEQ ID NO: 2 in Sequence listing, and which has an activity of
25 aspartate aminotransferase.

7). The bacterium according to claim 5, wherein the aspartate aminotransferase
gene comprises the following DNA (a) or (b):

(a) a DNA which comprises a nucleotide sequence of the nucleotides 1 to 1196 in
SEQ ID NO: 1; or

30 (b) a DNA which is hybridizable with a nucleotide sequence of the nucleotides 1-
1196 in SEQ ID NO:1 or a probe which can be prepared from the nucleotide sequence
under the stringent conditions and codes for a protein having an activity of aspartate
aminotransferase.

8). The bacterium according to claim 7, wherein the stringent conditions is a condition in which washing is performed at 60°C, and at a salt concentration corresponding to 1 x SSC and 0.1 % SDS.

9). The bacterium according to any of claims 1 to 8, wherein the bacterium has been further modified to enhance expression of one or more genes selected from the group consisting of

- the mutant *thrA* gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine;
- the *thrB* gene, which codes for homoserine kinase;
- the *thrC* gene, which codes for threonine synthase;
- the *rhtA* gene, which codes for putative transmembrane protein.

10). The bacterium according to claim 9, wherein the bacterium has been modified to increase expression amount of the mutant *thrA* gene, the *thrB* gene, the *thrC* gene and the *rhtA* gene.

11). A method for producing L- threonine, which comprises cultivating the bacterium according to any of claims 1 to 10 in a culture medium to produce and accumulate L-threonine in the culture medium, and collecting the L-threonine from the culture medium.

Abstract of disclosure

There is disclosed a method for producing L-threonine using bacterium
belonging to the genus *Escherichia* wherein the bacterium has L- threonine productivity
5 and has been modified to enhance an activity of aspartate aminotransferase.